Cardiotoxicity in Breast Cancer Treatments
Author Information
Author(s): Murg Sergiu Ioan, Matiș Loredana, Moldovan Andrada Florina, Schwarz-Madar Andrada Florina, Trifan Daniela Florina, Ghitea Timea Claudia, Popescu Mircea Ioachim
Primary Institution: University of Oradea
Hypothesis
This study evaluates the cardiotoxic effects of cytostatic treatments and their relationship with tumor characteristics.
Conclusion
The study highlights the need for personalized treatment protocols to minimize cardiotoxicity and improve the quality of life for oncology patients.
Supporting Evidence
- Patients with advanced-stage cancer showed a significant reduction in left ventricular ejection fraction (LVEF).
- Biomarker assessments indicated early signs of cardiotoxicity before clinical symptoms emerged.
- Regular cardiac monitoring can help identify high-risk patients early.
Takeaway
Cancer treatments can hurt the heart, so doctors need to watch for heart problems while treating cancer to keep patients safe.
Methodology
A retrospective analysis of cancer patients treated with anthracyclines, HER2-targeted therapies, and radiotherapy, monitoring cardiac function via echocardiography.
Limitations
The study lacks long-term data on newer therapies and needs more research on late-stage cardiovascular effects.
Participant Demographics
The cohort comprised 5149 female patients aged 20–88 years, with 39.7% having comorbidities.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website